Effects of sildenafil and tadalafil on skin flap viability

Arch Dermatol Res. 2022 Mar;314(2):151-157. doi: 10.1007/s00403-021-02196-0. Epub 2021 Mar 14.

Abstract

Vascular complication is one of the causes of skin flap healing failure. Sildenafil and tadalafil, a type-5 phosphodiesterase inhibitor, can improve flap viability, however, the action mechanisms involved in this process are still unclear. To assess the effects of orally administered sildenafil and tadalafil on the healing kinetics and skin flap viability, sixty-two Wistar rats were divided into three groups: control (n = 22), sildenafil (n = 20), and tadalafil (n = 20). The solutions were administered orally (dose: 10 mg/kg) immediately after the surgical procedure and then every 24 h. At postoperative days 7 and 14, the skin flap samples were collected, submitted to histological processing and evaluated under optical microscopy. In experimental groups (sildenafil and tadalafil), we found an increased vascularization (p < 0.05) on the 7th and 14th day associated with the ulcer size decrease on the 14th day, although it was not significant. There was a higher influx of neutrophils and a decrease of mononuclear population on the 7th day (p < 0.05). On the 14th day, these differences were observed only in the tadalafil group (p < 0.05). This study suggested positive results with the use of sildenafil and tadalafil as adjuvant drugs in skin flap viability.

Keywords: Flap viability; Healing; Type-5 phosphodiesterase inhibitor.

MeSH terms

  • Administration, Oral
  • Animals
  • Male
  • Models, Animal
  • Rats
  • Rats, Wistar
  • Sildenafil Citrate / administration & dosage
  • Sildenafil Citrate / pharmacology*
  • Skin Neoplasms / surgery*
  • Skin Transplantation*
  • Surgical Flaps*
  • Tadalafil / administration & dosage
  • Tadalafil / pharmacology*
  • Vasodilator Agents / administration & dosage
  • Vasodilator Agents / pharmacology*
  • Wound Healing / drug effects*

Substances

  • Vasodilator Agents
  • Tadalafil
  • Sildenafil Citrate